On the interest of PET with 18F-FDG in the management of cancer of unknown primary (CUP);Impact de la tomographie par émission de positons au 18fluorodésoxyglucose dans la prise en charge des cancers de primitif inconnu

Medecine Nucleaire

Volumn 31, Issue 5, 2007, Pages 242-249

  Bruna, C ^a   Journo, A ^a   Netter, F ^a   Kaminsky, M C ^b   Dolivet, G ^b   Olivier, P ^a   Karcher, G ^a  

^a CHU NANCY BRABOIS   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

Author keywords

Cancer of unknown primary; CUP; FDG; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BRAIN CANCER; CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; METASTASIS; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; THYROID CANCER; UTERUS CANCER;

EID: 34250216358     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mednuc.2006.10.001     Document Type: Article

References (46)

1. Pavlidis N., Briasoulis E., Hainsworth J., and Greco F.A. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39 (2003) 1990-2005
2. Levi F., Te V.C., Erler G., Randimbison L., and La Vecchia C. Epidemiology of unknown primary tumours. Eur J Cancer 38 (2002) 1810-1812
3. Ghosh L., Dahut W., Kakar S., Posadas E.M., Torres C.G., Cancel-Santiago R., et al. Management of patients with metastatic cancer of unknown primary. Curr Probl Surg 42 (2005) 12-66
4. Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann Oncol 14 (2003) 1-8
5. Al-Brahim N., Ross C., Carter B., and Chorneyko K. The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center. Ann Diagn Pathol 9 (2005) 77-80
6. Lortholary A., Abadie-Lacourtoisie S., Guerin O., Mege M., Rauglaudre GD., and Gamelin E. Cancers d'origine indéterminée : à propos de 311 cas. Bull Cancer 88 (2001) 619-627
7. Culine S., Kramar A., Saghatchian M., Bugat R., Lesimple T., Lortholary A., et al. French study group on carcinomas of unknown primary. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20 (2002) 4679-4683
8. Hess K.R., Abbruzzese M.C., Lenzi R., Raber M.N., and Abbruzzese J.L. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5 (1999) 3403-3410
9. Lesimple T., Voigt J.J., Bataillard A., Coindre J.M., Culine S., Lortholary A., et al. FNCLCC recommandations pour la pratique clinique : standards, options et recommandations pour les carcinomes de site primitif inconnu. Bull Cancer 90 (2003) 1071-1096
10. Bourguet P. Groupe de Travail SOR. Standards, options et recommandations 2002 pour l'usage de la tomographie à émission de positons au [18F]-FDG en cancérologie. Résultats dans les cancers de site primitif inconnu. Bull Cancer 90 (2003) S5-17
11. Jereczek-Fossa B.A., Jassem J., and Orecchia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev 30 (2004) 153-164
12. Rusthoven K.E., Koshy M., and Paulino A.C. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101 (2004) 2641-2649
13. Braams J.W., Pruim J., Kole A.C., Nikkels P.G., Vaalburg W., Vermey A., et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 26 (1997) 112-115
14. Safa A.A., Tran L.M., Rege S., Brown C.V., Mandelkern M.A., Wang M.B., et al. The role of positron emission tomography in occult primary head and neck cancers. Cancer J Sci Am 5 (1999) 214-218
15. Greven K.M., Keyes J.J., Williams D.3r., McGuirt W.F., and Joyce W.3r. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer 86 (1999) 114-118
16. Stokkel M.P., Terhaard C.H., Hordijk G.J., and van Rijk P.P. The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography. Oral Oncol 35 (1999) 390-394
17. Assar O.S., Fischbein N.J., Caputo G.R., Kaplan M.J., Price D.C., Singer M.I., et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 210 (1999) 177-181
18. Jungehulsing M., Scheidhauer K., Damm M., Pietrzyk U., Eckel H., Schicha H., et al. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 123 (2000) 294-301
19. Perie S., Talbot J.N., Monceaux G., Grahek D., Kerrou K., Montravers F., et al. Use of a coincidence gamma camera to detect primary tumor with 18fluoro-2-deoxy-glucose in cervical lymph node metastases from an unknown origin. Ann Otol Rhinol Laryngol 109 (2000) 755-760
20. Bohuslavizki K.H., Klutmann S., Sonnemann U., Thoms J., Kroger S., Werner J.A., et al. F-18 FDG PET for detection of occult primary tumor in patients with lymphatic metastases of the neck region. Laryngorhinootologie 78 (1999) 445-449
21. Fogarty G.B., Peters L.J., Stewart J., Scott C., Rischin D., and Hicks R.J. The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck 25 (2003) 138-145
22. Regelink G., Brouwer J., de Bree R., Pruim J., van der Laan B.F., Vaalburg W., et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging 29 (2002) 1024-1030
23. Johansen J., Eigtved A., Buchwald C., Theilgaard S.A., and Hansen H.S. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope 112 (2002) 2009-2014
24. Stoeckli S.J., Mosna-Firlejczyk K., and Goerres G.W. Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography. Eur J Nucl Med Mol Imaging 30 (2003) 411-416
25. Wong W.L., and Saunders M. The impact of FDG PET on the management of occult primary head and neck tumours. Clin Oncol (R Coll Radiol) 15 (2003) 461-466
26. Freudenberg L.S., Fischer M., Antoch G., Jentzen W., Gutzeit A., Rosenbaum S.J., et al. Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract 14 (2005) 155-160
27. Kole A.C., Nieweg O.E., Pruim J., Hoekstra H.J., Koops H.S., Roodenburg J.L., et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 82 6 (1998) 1160-1166
28. Lassen U., Daugaard G., Eigtved A., Damgaard K., and Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 35 (1999) 1076-1082
29. Bohuslavizki K.H., Klutmann S., Kroger S., Sonnemann U., Buchert R., Werner J.A., et al. FDG PET detection of unknown primary tumors. J Nucl Med 41 (2000) 816-822
30. Trampal C., Sorensen J., Engler H., and Langstrom B. 18F-FDG whole body Positron Emission Tomography (PET) in the detection of unknown primary tumors. Clin Positron Imaging 3 (2000) 160
31. Rades D., Kuhnel G., Wildfang I., Borner A.R., Schmoll H.J., and Knapp W. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 12 (2001) 1605-1609
32. Lonneux M., and Reffad A. Metastases from unknown primary tumor PET-FDG as initial diagnostic procedure?. Clin Positron Imaging 3 (2000) 137-141
33. Scott C.L., Kudaba I., Stewart J.M., Hicks R.J., and Rischin D. The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin. Mol Imaging Biol 7 (2005) 236-243
34. Klee B., Law I., Hojgaard L., and Kosteljanetz M. Detection of unknown primary tumours in patients with cerebral metastases using whole-body 18F-flouorodeoxyglucose positron emission tomography. Eur J Neurol 9 (2002) 657-662
35. Mantaka P., Baum R.P., Hertel A., Adams S., Niessen A., Sengupta S., et al. PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patients' diagnostic and therapeutic management. Cancer Biother Radiopharm 18 (2003) 47-58
36. Joshi U., van der Hoeven J.J., Comans E.F., Herder G.J., Teule G.J., and Hoekstra O.S. In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDG-PET. Br J Radiol 77 (2004) 1000-1006
37. Nanni C., Rubello D., Castellucci P., Farsad M., Franchi R., Toso S., et al. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 32 (2005) 589-592
38. Kolesnikov-Gauthier H., Levy E., Merlet P., Kirova J., Syrota A., Carpentier P., et al. FDG PET in patients with cancer of an unknown primary. Nucl Med Commun 26 (2005) 1059-1066
39. Dede F., Ajoedi N.D., Ansari S.M., Jana S., Heiba S.I., and Abdel-Dayem H.M. Metastatic thyroid cancer occurring as an unknown primary lesion: the role of F-18 FDG positron emission tomography. Clin Nucl Med 26 (2001) 396-399
40. Ruiz-Ruiz F.J., Saenz-Abad D., Hualde-Enguita A.M., and Morales-Rull J.L. Positron emission tomography: useful in detecting metastatic cancer of unknown primary site. Singapore Med J 46 (2005) 302-303
41. Delgado-Bolton R.C., Fernandez-Perez C., Gonzalez-Mate A., and Carreras J.L. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 44 (2003) 1301-1314
42. Jeong H.J., Chung J.K., Kim Y.K., Kim C.Y., Kim D.G., Jeong J.M., et al. Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain tumors. J Nucl Med 43 (2002) 1432-1437
43. Alberini J.L., Belhocine T., Hustinx R., Daenen F., and Rigo P. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome). Nucl Med Commun 24 (2003) 1081-1086
44. Gutzeit A., Antoch G., Kuhl H., Egelhof T., Fischer M., Hauth E., et al. Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology 234 (2005) 227-234
45. Pelosi E., Pennone M., Deandres D., Douroukas A., Mancini M., and Bisi G. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 50 (2006) 15-22
46. Talbot J.N., Kerrou K., Gutman F., Perie S., Grahek D., Roulet E., et al. FDG-PET in localization of cancers of unknown primary origin. Presse Med 35 (2006) 1371-1376